It also enhances the cytotoxic activity of intratumoral CD8+ T-cells, as preclinical models have shown that the de novo expression of recombinant IL-10 results in CD8+ T-cell-mediated tumor rejection [83]. The gene discussed is CD8A; the disease is neoplasm.